Scott Liu

Co-Founder, President and CEO, Shanghai Henlius Biotech Inc.


Scott Liu is one of the global partners of Fosun International Limited and the Co-Founder, President and CEO at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. 

Under his leadership, Henlius has become a leader of therapeutic monoclonal antibodies to treat a range of chronic and life-threatening diseases in China. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to joining Fosun Group in 2010, he served in several executive positions such as Vice President of R&D at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of QAL (QC) at Amgen (Fremont, USA). Drawing on his extensive knowledge in quality and control of biologics, Dr. Liu provided assistance to the Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) in developing and implementing quality standards for biosimilars and novel biologics in China. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China.

Dr. Liu was the recipient of the “Technical Operations Presidential Award” by Bristol-Myers Squibb in 2004 and was recognized in 2013 as an expert of the "Thousand Talents Plan of Shanghai”. Dr. Liu received his Ph.D. degree in Biology from the Purdue University with postdoctoral training in Biology at Stanford University and studied business administration (iMBA courses) at the Syracuse University.